Skye Bioscience Inc (SKYE)
5.50
-1.96
(-26.27%)
USD |
NASDAQ |
Jul 05, 16:00
5.61
+0.11
(+2.00%)
After-Hours: 20:00
Skye Bioscience Research and Development Expense (Annual): 5.820M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.820M |
| December 31, 2022 | 6.012M |
| December 31, 2021 | 2.931M |
| December 31, 2020 | 1.944M |
| December 31, 2019 | 2.238M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.33M |
| December 31, 2017 | 0.3113M |
| December 31, 2016 | 0.939M |
| December 31, 2015 | 0.5761M |
| December 31, 2014 | 0.2275M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.944M
Minimum
2020
6.012M
Maximum
2022
3.789M
Average
2.931M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Cutera Inc | 21.41M |
| Zymeworks Inc | 143.62M |
| OrthoPediatrics Corp | 10.20M |
| RAPT Therapeutics Inc | 101.00M |
| NovaBay Pharmaceuticals Inc | 0.068M |